Nanoparticles functionalized with ampicillin destroy multiple-antibiotic-resistant isolates of Pseudomonas aeruginosa and Enterobacter aerogenes and methicillin-resistant Staphylococcus aureus

Applied and Environmental Microbiology

Volumn 78, Issue 8, 2012, Pages 2768-2774

  Brown, Ashley N ^a   Smith, Kathryn ^a   Samuels, Tova A ^a   Lu, Jiangrui ^a   Obare, Sherine O ^a   Scott, Maria E ^a  

^a WESTERN MICHIGAN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC RESISTANCE; BACTERICIDAL AGENT; ENTEROBACTER AEROGENES; FUNCTIONALIZED; GOLD NANOPARTICLE; GRAM-POSITIVE BACTERIUM; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MULTIPLE-DRUG-RESISTANT BACTERIUM; PSEUDOMONAS AERUGINOSA; SILVER NANOPARTICLES;

ANTIBIOTICS; BACTERICIDES; NANOPARTICLES; SILVER;

BACTERIA;

AMPICILLIN; ANTIINFECTIVE AGENT; GOLD; NANOPARTICLE; SILVER;

ANTIBIOTIC RESISTANCE; ANTIBIOTICS; BACTERIUM; GOLD; NANOTECHNOLOGY; SILVER;

ARTICLE; BACTERIAL COUNT; DRUG EFFECT; ENTEROBACTER AEROGENES; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL VIABILITY; MULTIDRUG RESISTANCE; PSEUDOMONAS AERUGINOSA;

AMPICILLIN; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTER AEROGENES; GOLD; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL VIABILITY; NANOPARTICLES; PSEUDOMONAS AERUGINOSA; SILVER;

ENTEROBACTER AEROGENES; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEGIBACTERIA; POSIBACTERIA; PSEUDOMONAS AERUGINOSA;

EID: 84861163968     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.06513-11     Document Type: Article

References (44)

1. Aymonier C, et al. 2002. Hybrids of silver nanoparticles with amphiphilic hyperbranched macromolecules exhibiting antimicrobial properties. Chem. Commun. (Camb.) 2002:3018-3019.
2. Bar-Ilan O, Albrecht RM, Fako VE, Furgeson DY. 2009. Toxicity assessments of multisized gold and silver nanoparticles in zebrafish embryos. Small 5:1897-1910.
3. Bechet D, et al. 2008. Nanoparticles as vehicles for delivery of photodynamic therapy agents. Trends Biotechnol. 26:612-621.
4. Boisselier E, Astruc D. 2009. Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies, and toxicity. Chem. Soc. Rev. 38:1759-1782.
5. Burygin GL, et al. 2009. On the enhanced antibacterial activity of antibiotics mixed with gold nanoparticles. Nanoscale Res. Lett. 4:794-801.
6. Cao H, Liu X. 2010. Silver nanoparticles: modified films versus biomedical device-associated infections. Wiley Interdiscipl. Rev. Nanomed. Nanobiotechnol. 2:670-684.
7. Carlson C, et al. 2008. Unique cellular interaction of silver nanoparticles: size-dependent generation of reactive oxygen species. J. Phys. Chem. B 112:13608-13619.
8. CDC. 2010. National antimicrobial resistance monitoring system for enteric bacteria (NARMS) human isolates final report, p 1-73. U.S. Department of Health and Human Services, Atlanta, GA.
9. Chaloupka K, Malam Y, Seifalian AM. 2010. Nanosilver as a new generation of nanoproduct in biomedical applications. Trends Biotechnol. 28:580-588.
10. Cho KH, Park JE, Osaka T, Park SG. 2005. The study of antimicrobial activity and preservative effects of nanosilver ingredient. Electrochim. Acta 51:956-960.
11. Choi O, et al. 2008. The inhibitory effects of silver nanoparticles, silver ions, and silver chloride colloids on microbial growth. Water Res. 42: 3066-3074.
12. Ciptadjaya CG, Guo W, Angeli JM, Obare SO. 2009. Controlling the reactivity of chlorinated ethylenes with flavin mononucleotide hydroquinone. Environ. Sci. Technol. 43:1591-1597.
13. Cobley CM, Chen J, Cho EC, Wang LV, Xia Y. 2011. Gold nanostructures: a class of multifunctional materials for biomedical applications. Chem. Soc. Rev. 40:44-56.
14. Fako VE, Furgeson DY. 2009. Zebrafish as a correlative and predictive model for assessing biomaterial nanotoxicity. Adv. Drug Deliv. Rev. 61: 478-486.
15. Fayaz AM, et al. 2010. Biogenic synthesis of silver nanoparticles and their synergistic effect with antibiotics: a study against gram-positive and gramnegative bacteria. Nanomedicine 6:103-109.
16. Grace AN, Pandian K. 2007. Antibacterial efficacy of aminoglycosidic antibiotics protected gold nanoparticles: a brief study. Colloids Surf. A 297:63-70.
17. Grant SG, Jessee J, Bloom FR, Hanahan D. 1990. Differential plasmid rescue from transgenic mouse DNAs into Escherichia coli methylationrestriction mutants. Proc. Natl. Acad. Sci. U. S. A. 87:4645-4649.
18. Gu H, Ho P, Tong E, Wang L, Xu B. 2003. Presenting vancomycin on nanoparticles to enhance antimicrobial activities. Nano Lett. 3:1261-1263.
19. Guo W, Ciptadjaya CGE, Liu M, Simms CM, Obare SO. 2009. Modulating the oxidation ofFMNH2 by organophosphorus compounds. J. Adv. Oxidation Technol. 11:459-462.
20. Hidron AI, et al. 2008. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect. Control Hosp. Epidemiol. 29:996-1011.
21. Hirst TR, Sanchez J, Kaper JB, Hardy SJ, Holmgren J. 1984. Mechanism of toxin secretion by Vibrio cholerae investigated in strains harboring plasmids that encode heat-labile enterotoxins of Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 81:7752-7756.
22. Karmali MA, Steele BT, Petric M, Lim C. 1983. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet i:619-620.
23. Kurek A, Grudniak AM, Kraczkiewicz-Dowjat A, Wolska KI. 2011. New antibacterial therapeutics and strategies. Pol. J. Microbiol. 60:3-12.
24. Li P, Li J, Wu C, Wu Q, Li J. 2005. Synergistic antibacterial effects of beta-lactam antibiotic combined with silver nanoparticles. Nanotechnology 16:1912-1917.
25. Li WR, et al. 2010. Antibacterial activity and mechanism of silver nanoparticles on Escherichia coli. Appl. Microbiol. Biotechnol. 85:1115-1122.
26. Morones JR, et al. 2005. The bactericidal effect of silver nanoparticles. Nanotechnology 16:2346-2353.
27. Neidhardt FC, Bloch PL, Smith DF. 1974. Culture medium for enterobacteria. J. Bacteriol. 119:736-747.
28. Nikaido H. 1985. Role of permeability barriers in resistance to betalactam antibiotics. Pharmacol. Ther. 27:197-231.
29. Obare SO, Hollowell RE, Catherine JM. 2002. Sensing strategy for lithium ion based on gold nanoparticles. Langmuir 18:10407-10410.
30. Pal S, Tak YK, Song JM. 2007. Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the Gram-negative bacterium Escherichia coli. Appl. Environ. Microbiol. 73: 1712-1720.
31. Panacek A, et al. 2006. Silver colloid nanoparticles: synthesis, characterization, and their antibacterial activity. J. Phys. Chem. B 110:16248-16253.
32. Park HJ, Kim et al. 2009. Silver-ion-mediated reactive oxygen species generation affecting bactericidal activity. Water Res. 43:1027-1032.
33. Rai M, Yadav A, Gade A. 2009. Silver nanoparticles as a new generation of antimicrobials. Biotechnol. Adv. 27:76-83.
34. Ravindranath SP, Henne KL, Thompson DK, Irudayaraj J. 2011. Surface-enhanced Raman imaging of intracellular bioreduction of chromate in Shewanella oneidensis. PLoS One 6:e16634.
35. Riley LW, et al. 1983. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N. Engl. J. Med. 308:681-685.
36. Saha B, et al. 2007. In vitro structural and functional evaluation of gold nanoparticles conjugated antibiotics. Nanoscale Res. Lett. 2:614-622.
37. Shahverdi AR, Fakhimi A, Shahverdi HR, Minaian S. 2007. Synthesis and effect of silver nanoparticles on the antibacterial activity of different antibiotics against Staphylococcus aureus and Escherichia coli. Nanomedicine 3:168-171.
38. Silver LL. 2011. Challenges of antibacterial discovery. Clin. Microbiol. Rev. 24:71-109.
39. Smith TC, et al. 2009. Methicillin-resistant Staphylococcus aureus (MRSA) strain ST398 is present in midwestern U.S. swine and swine workers. PLoS One 4:e4258.
40. Sondi I, Salopek-Sondi B. 2004. Silver nanoparticles as antimicrobial agent: a case study on Escherichia coli as a model for Gram-negative bacteria. J. Colloid Interface Sci. 275:177-182.
41. Tom RT, Suryanarayanan V, Reddy PG, Baskaran S, Pradeep T. 2004. Ciprofloxacin-protected gold nanoparticles. Langmuir 20:1909-1914.
42. Veerapandian M, Lim SK, Nam HM, Kuppannan G, Yun KS. 2010. Glucosamine-functionalized silver glyconanoparticles: characterization and antibacterial activity. Anal. Bioanal. Chem. 398:867-876.
43. Wei D, Sun W, Qian W, Ye Y, Ma X. 2009. The synthesis of chitosanbased silver nanoparticles and their antibacterial activity. Carbohydr. Res. 344:2375-2382.
44. Yoon KY, Hoon BJ, Park JH, Hwang J. 2007. Susceptibility constants of Escherichia coli and Bacillus subtilis to silver and copper nanoparticles. Sci. Total Environ. 373:572-575.